

Tan-Peng Zhou, Meng-Meng Cao, Jun-Ya Du, Jing Yang* and Xia Wang

Crystal structure of poly[μ₂-dichlorido-(μ₂-1-[(2,4-dimethyl-1*H*-triazole-1-yl)methyl]-1*H*-benzotriazole-κ²N:N')cadmium(II)], C₁₁H₁₂CdN₆Cl₂

<https://doi.org/10.1515/ncrs-2024-0082>

Received February 22, 2024; accepted April 27, 2024;
published online May 24, 2024

Abstract

C₁₁H₁₂CdN₆Cl₂, triclinic, *P* $\bar{1}$ (no. 2), *a* = 6.8644(8) Å, *b* = 10.4577(8) Å, *c* = 10.6304(12) Å, α = 112.218(9)°, β = 94.638(9)°, γ = 93.289(8)°, *Z* = 2, *V* = 700.93(13) Å³, *R*_{gt}(*F*) = 0.0427, *wR*_{ref}(*F*²) = 0.1137, *T* = 293(2) K.

CCDC no.: 2351582

Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

1 Source of materials

1-[(2,4-Dimethyl-1*H*-triazole-1-yl)methyl]-1*H*-benzotriazole (dtmb) was prepared according to the literature method with some modifications.³ The ligand 1-[(2,4-dimethyl-1*H*-triazole-1-yl)methyl]-1*H*-benzotriazole (0.04 mmol, 0.0091 g) was dissolved in 2 mL of methanol solution and the solution was slowly added to 2 mL of CdCl₂ (0.04 mmol, 0.0074 g) of methanol solution. The prepared solution was placed at room temperature and colorless crystals were obtained after ten days.

2 Experimental details

H atoms were generated geometrically and refined as riding atoms with C–H = 0.93 Å and the and *U*_{iso}(H) = 1.2 times *U*_{eq}(C) for aromatic H atoms, with C–H = 0.97 Å and *U*_{iso}(H) = 1.2 times *U*_{eq}(C) for methylene H atoms, and with C–H = 0.96 Å and *U*_{iso}(H) = 1.5 times *U*_{eq}(C) for methyl H atoms.


*Corresponding author: Jing Yang, College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, P.R. China, E-mail: candyjy@163.com. <https://orcid.org/0000-0002-4427-2214>
Tan-Peng Zhou, Meng-Meng Cao, Jun-Ya Du and Xia Wang, College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, P.R. China. <https://orcid.org/0000-0002-7929-0383> (X. Wang)

Table 1: Data collection and handling.

Crystal:	Colorless block
Size:	0.21 × 0.16 × 0.12 mm
Wavelength:	Cu Kα radiation (1.54184 Å)
μ:	16.0 mm ^{−1}
Diffractionmeter, scan mode:	Xcalibur, ω
θ _{max} , completeness:	67.1°, >99 %
<i>N</i> (<i>hkl</i>) _{measured} , <i>N</i> (<i>hkl</i>) _{unique} , <i>R</i> _{int} :	4999, 2496, 0.046
Criterion for <i>I</i> _{obs} , <i>N</i> (<i>hkl</i>) _{gt} :	<i>I</i> _{obs} > 2 σ(<i>I</i> _{obs}), 2180
<i>N</i> (<i>param</i>) _{refined} :	184
Programs:	CrysAlis ^{PRO} , ¹ SHELX ²

Table 2: Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å²).

Atom	<i>x</i>	<i>y</i>	<i>z</i>	<i>U</i> _{iso} ^{*/} <i>U</i> _{eq}
Cd1	1.24229 (6)	0.41604 (4)	0.00383 (4)	0.02454 (19)
Cl1	1.4141 (2)	0.55211 (15)	−0.13167 (15)	0.0306 (3)
Cl2	1.0845 (2)	0.62841 (14)	0.16241 (15)	0.0305 (3)
N1	0.6855 (8)	−0.1936 (5)	0.1586 (5)	0.0280 (11)
N2	0.6556 (7)	−0.0944 (5)	0.1169 (5)	0.0277 (11)
N3	0.6622 (7)	0.0250 (5)	0.2277 (5)	0.0257 (11)
N4	0.8379 (7)	0.2190 (5)	0.2039 (5)	0.0246 (10)
N5	0.9418 (8)	0.3111 (5)	0.3228 (5)	0.0299 (12)
N6	1.0931 (8)	0.2961 (5)	0.1382 (5)	0.0265 (11)
C1	0.7292 (10)	0.0908 (7)	0.4843 (6)	0.0347 (15)
H1	0.7244	0.1863	0.5140	0.042*
C2	0.7634 (10)	0.0264 (7)	0.5729 (6)	0.0365 (15)
H2	0.7822	0.0802	0.6662	0.044*
C3	0.7714 (11)	−0.1182 (8)	0.5292 (7)	0.0382 (16)
H3	0.7925	−0.1569	0.5943	0.046*
C4	0.7489 (10)	−0.2030 (7)	0.3936 (7)	0.0339 (15)
H4	0.7568	−0.2981	0.3648	0.041*
C5	0.7135 (9)	−0.1399 (6)	0.3002 (6)	0.0262 (13)
C6	0.7016 (8)	0.0029 (6)	0.3448 (6)	0.0245 (12)
C7	0.6488 (9)	0.1542 (6)	0.2090 (7)	0.0310 (14)
H7A	0.5663	0.1368	0.1247	0.037*
H7B	0.5865	0.2175	0.2837	0.037*
C8	0.9287 (9)	0.2115 (6)	0.0962 (6)	0.0252 (13)
C9	1.0921 (10)	0.3547 (6)	0.2782 (6)	0.0287 (13)
C10	0.8543 (10)	0.1183 (7)	−0.0458 (6)	0.0333 (14)
H10A	0.7559	0.1611	−0.0814	0.050*
H10B	0.7981	0.0319	−0.0464	0.050*
H10C	0.9607	0.1016	−0.1015	0.050*
C11	1.2531 (11)	0.4570 (8)	0.3748 (6)	0.0405 (17)
H11A	1.3661	0.4094	0.3827	0.061*
H11B	1.2082	0.5001	0.4630	0.061*
H11C	1.2876	0.5267	0.3400	0.061*



3 Comment

Recently, nitrogen heterocyclic compounds have attracted a lot of attention in the field of metal coordination polymers due to their flexible coordination patterns and rich functional properties.^{4–6} Among them, triazole and benzotriazole compounds are rich in biological activities such as antibacterial, anti-inflammatory, anti-cancer and anti-diabetes. Metallic polymers synthesized with them as ligands have also been found to have beneficial effects in antibacterial, antioxidant, anti-cancer, hypoglycemic, etc.^{7–10} Previously, our group also successfully synthesized complexes with nitrogen heterocycles as ligands, among which complexes were investigated to have better antidiabetic activity.¹¹

X-ray crystallographic analysis shows that the title polymer has a two-dimensional network structure centered on a binuclear Cd(II). As shown in the Figure, the central atom Cd(II) is coordinated with four Cl ions (Cl1, Cl1i, Cl2 and Cl2ii) and two N atoms (N1iii and N6) from two dtmb ligands, respectively. The Cd–Cl and Cd–N bonds around Cd1 are of length: Cd1–Cl1: 2.6689(16) Å; Cd1–Cl1i: 2.5630(15) Å; Cd1–Cl2: 2.5861(14) Å; Cd1–Cl2i: 2.6436(16) Å; Cd1–N1iii: 2.423(5) Å; Cd1–N6: 2.471(5) Å. The range of bond angles around the Cd is 84.16(12)°–177.51(12)°.¹² The smallest bond angle is N6–Cd1–Cl2, the largest is N6–Cd1–Cl1, in each dtmb ligand, the angle between the benzotriazole and the triazole ring is 67.0°, and two adjacent cadmium ions are connected by two dtmb ligands in a bidentate bridging coordination mode to form a binuclear structure. The dinuclear Cd(II) asymmetric unit extends indefinitely by connecting two Cl ions to form a two-dimensional structure. In addition, the distance between the benzotriazole

rings of two neighboring binuclear units is 3.716 Å, which may have intermolecular p-p interactions, and the two-dimensional mesh structure is expanded into three-dimensional, making the structure more stable.

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: This work was financially supported by the Key Scientific and Research Projects of the Education Department of Henan Province (No. 21A430024).

Conflict of interest statement: The authors declare no conflicts of interest regarding this article.

References

1. Baker D., Jones A. *Agilent Technologies: CrysAlis^{PRO} Software System, version 171.37.35*; Agilent Technologies UK Ltd: Oxford, UK, 2014.
2. Sheldrick, G. M. A short history of SHELX. *Acta Crystallogr.* **2008**, A64, 112–122.
3. Katritzky, A.-R.; Drewniak-Deyrup, M.; Lan, X.-F.; Brunner, F. Chemistry of benzotriazole. Preparation, lithiation and transformation of *N*-(benzotriazol-1-ylmethyl) heterocycles. *J. Heterocycl. Chem.* **1989**, 26, 829–836.
4. Mariwamy, V. H.; Kollur, S. P.; Shivananda, B.; Begum, M.; Shivamallu, C.; Dharmashekara, C.; Pradeep, S.; Jain, A. S.; Prasad, S. K.; Syed, A.; Elgorban, A. M.; Al-Rejaie, S.; Ortega-Castro, J.; Frau, J.; Flores-Holguín, N.; Glossman-Mitnik, D. *N*-((1*H*-Pyrrol-2-yl)methylene)-6-methoxypyridin-3-amine and its Co(II) and Cu(II) complexes as antimicrobial agents: Chemical preparation, in vitro antimicrobial evaluation, in silico analysis and computational and theoretical chemistry investigations. *Molecules* **2022**, 27, 1436.
5. Ibrahim, H. M.; Behbehani, H.; Elnagdi, M. H. Approaches towards the synthesis of a novel class of 2-amino-5-arylazonicotinate, pyridazinone and pyrido[2,3-*d*] pyrimidine derivatives as potent antimicrobial agents. *Chem. Cent. J.* **2013**, 7, 123.
6. Timmons, J. C.; Hubin, T. J. Preparations and applications of synthetic linked azamacrocyclic ligands and complexes. *Coord. Chem. Rev.* **2010**, 254, 1661–1685.
7. Alamier, W. M.; Alaghaz, A. M. A. Design, spectral characterization, quantum chemical investigation, biological activity of nano-sized transition metal complexes of tridentate 3-mercapto-4*H*-1,2,4-triazol-4-yl-aminomethylphenol Schiff base ligand. *J. Biomol. Struct. Dyn.* **2023**, 2023, 1–21.
8. Seddik, R. G.; Shoukry, A. A.; Rashidi, F. B.; Salah-Eldin, D. S. Investigation on CT-DNA and protein interaction of new Pd(II) complexes involving ceftazidime and 3-amino-1,2,3-triazole: Synthesis, characterization, biological impact, anticancer evaluation, and molecular docking approaches. *Chem. Biodivers.* **2023**, 12, e202301170.
9. Wei, X.; Li, J. H.; Huang, Q. Y.; Meng, X. R. Two new isostructural mercury(II) complexes involving the *N*-heterocyclic 1-[(benzotriazol-1-yl)methyl]-1*H*-1,3-imidazole ligand: syntheses, structures and properties. *Acta Crystallogr.* **2017**, C73, 314–318.
10. Abuelizz, H. A.; Awad, H. M.; Marzouk, M.; Nasr, F. A.; Alqahtani, A. S.; Bakheit, A. H.; Naglah, A. M.; Al-Salahi, R. Synthesis and biological evaluation of 4-(1*H*-1,2,4-triazol-1-yl) benzoic acid hybrids as anticancer agents. *RSC Adv.* **2019**, 9, 19065–19074.

11. Wang, X.; Du, J. Y.; Zhou, T. P.; Fang, X.; Yang, H. X. Novel benzotriazole-benzimidazole metal complexes: structure-activity relationship, synthesis, characterization, and antidiabetic activity. *J. Mol. Struct.* **2023**, 1292, 136141.
12. Zhao, D.; Xiu, Y.; Zhou, X.-L.; Meng, X.-R. Syntheses, structures, and fluorescent properties of two new d10-metal coordination polymers containing 1-((benzotriazol-1-yl)methyl)-1-H-1,2,4-triazole ligand. *J. Coord. Chem.* **2012**, 65, 112–121.